关于Brivanib
Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma+ Author Affiliations1Center for Liver Cancer, National Cancer Center 2Div Hematology- Oncology, Geffen School of Medicine at UCLA 3Medical Oncology, Korea University 4Department of Internal Medicine, Holden Comprehensive Cancer Center at University of Iowa 5Oncology, St Lukes Medical Center 6Department of Radiotherapy and Oncology, Hospital Universiti Kebangsaan 7GI Medical Oncology, UNIT 426, UT M. D. Anderson Cancer Cente 8Bristol-Myers Squibb [*]9Department of Medical Oncology, Comprehensive Cancer Centre E Marquis, Rennes, France
[*]* Corresponding Author:
Joong-Won Park, Center for Liver Cancer, National Cancer Center, 809 Madu 1 dong, Ilsan-gu, Goyang, Gyeonggi, 411-764, Korea (South), Republic of jwpark@ncc.re.kr
AbstractPurpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and vascular endothelial growth factor signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response , or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization criteria (mWHO). According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% confidence interval ) was 2.7 (1.4- 3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.
Received July 27, 2010. Revision received January 5, 2011. [*]Accepted February 3, 2011.
请有Brivanib信息的朋友来更新一下呀 好久没有这药的信息了 本帖最后由 呼吸空气中 于 2011-7-27 23:31 编辑
bkcui 发表于 2011-7-27 17:39 static/image/common/back.gif
多靶点药物的冬天要到了，还是关注cabozantinib吧，希望之星
这个已经准备上了。我们肝的。多吉美耐药/ 索坦，要是也失去作用。也够头疼得了。。 为什么说多靶点药物的冬天要到了，难道是索坦再失去效果 这个类型的药物也就没什么可用的了。 bkcui 发表于 2011-12-26 21:39 static/image/common/back.gif
BMS的新药Brivanib在治疗多吉美失败的二线研究结果出来了，以失败的结果宣布结束。新药研究风险特别大，此前 ...
如果哪个药能进入胆管癌的二期临床我就已经兴奋的不得了了
页:
[1]
2